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The mechanism of peritoneal fibrosis in patients on
continuous ambulatory peritoneal dialysis (CAPD) is poorly
elucidated. We investigated the cellular mechanism of
high-glucose-induced expression of monocyte
chemoattractant protein-1 (MCP-1), which is important in
recruiting monocytes into the peritoneum and progression of
peritoneal fibrosis, and examined the inhibitory mechanism
of glucocorticoids. Rat peritoneal mesothelial cells were
cultured in high-glucose-containing medium and then
analyzed for phosphorylation levels of p42/44 and p38
mitogen-activated protein (MAP) kinases (MAPK), MAPK or
extracellular signal-regulated kinase kinase (MEK)1/2, c-Jun
N-terminal kinase (JNK)1/2, and protein kinase C (PKC) by
Western blotting. Expression of MCP-1 was examined by
reverse transcription-polymerase chain reaction and
enzyme-linked immunosorbent assay, respectively.
DNA-binding activity of nuclear factor (NF)-jB was measured
by electrophoretic mobility shift assay. High glucose
increased MCP-1 mRNA and MCP-1 protein expression.
Although glucose increased phosphorylation of MEK1/2, p42/
44 MAPK, p38 MAPK, JNK1/2, and PKC, and DNA-binding
activity of NF-jB, its effect on MCP-1 expression was
suppressed only by PKC and NF-jB inhibitors. Mannitol
caused a similar increase in PKC and NF-jB activation and
MCP-1 synthesis. Prednisolone increased I-jB-a expression
and inhibited glucose/mannitol-induced NF-jB DNA binding
and MCP-1 expression without affecting PKC
phosphorylation. The inhibitory effects of prednisolone on
MCP-1 expression were reversed by mifepristone, a
glucocorticoid receptor antagonist. Our results indicate that
glucose induces MCP-1 mainly through hyperosmolarity by
activating PKC and its downstream NF-jB, and that such
effect was inhibited by prednisolone, suggesting the efficacy
of prednisolone in preventing peritoneal fibrosis in patients
on CAPD.
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Progressive peritoneal fibrosis has been observed in patients
on long-term continuous ambulatory peritoneal dialysis
(CAPD). Morphological studies of the peritoneal membrane
in patients chronically exposed to dialysis solutions have
shown loss of mesothelial cells and replacement of the
membrane by collagen-based fibrous tissue.1,2 Furthermore,
some patients develop sclerosing encapsulating peritonitis, a
condition associated with high mortality.3 Therefore, there is
a pressing need for a peritoneal dialysate that is less harmful
to the peritoneal membrane and has fewer inflammatory and
fibrogenetic effects.
Abnormal remodeling of the extracellular matrix results
from a complex process that involves increased expression of
growth factors and cytokines, which lead to quantitative and
constitutional changes in extracellular matrix components.
The peritoneal dialysate, containing non-physiological ma-
terials such as hypertonic glucose, glucose degradation
products, and lactate-buffered acidic solution, is thought to
be toxic and is implicated in the long-term damage of the
peritoneal membrane.2,4 In particular, glucose plays an
important role in the pathogenesis of peritoneal fibrosis.
High glucose levels induce the expression of various
cytokines such as transforming growth factor-b5 and basic
fibroblast growth factor,6 which in turn lead to extracellular
matrix production such as fibronectin in mesothelial cells.7
In addition, glucose suppresses cell–cell or cell–extracellular
matrix adhesions of mesothelial cells followed by impaired
regeneration of mesothelial cells.8,9 Glucose is therefore
involved in the initiation and progression of peritoneal
damage.
The chemokines monocyte chemoattractant protein-1
(MCP-1) has been reported to have a high degree of
specificity as a chemotactic factor for monocytes and
macrophages, and plays an important role in the initiation
and progression of inflammatory processes in peritoneal
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fibrosis.10 Recent studies have shown that the concentration
of MCP-1 is increased in the dialysate effluent using
conventional glucose-containing dialysate.11 In addition,
specific antibody blocking studies have demonstrated a direct
role for mesothelial cell-derived MCP-1 in mediating
leukocyte migration across the mesothelial layer,12 indicating
that MCP-1 might play an important role in the progression
of peritoneal damage.
Induction of MCP-1 gene expression is mediated through
multiple intracellular signal pathways such as p42/44 and p38
mitogen-activated protein kinases (MAPK),13,14 protein
kinase C (PKC),15 focal adhesion kinase,16 and nuclear factor
(NF)-kB17,18 in glomerular mesangial cells. In mesothelial
cells, glucose is known to induce MCP-1 production through
several intracellular signaling pathways, such as PKC,19 and
partly by tyrosine kinase/activated protein (AP)-1 pathway.20
However, the precise intracellular molecular mechanism in
mesothelial cells remains to be elucidated.
Corticosteroids, especially prednisolone, are the pre-
eminent anti-inflammatory agents widely used to suppress
fibrosis such as that characteristic of various types of
glomerulonephritis, interstitial pneumonia, and collagen
diseases. Activation of glucocorticoid receptor (GR) results
in increased or decreased transcription of a number of genes
involved in the inflammatory process.21 Although gluco-
corticoids are also used for the treatment of peritoneal
impairment such as sclerosing encapsulating peritonitis,22 the
molecular mechanisms responsible for this efficacy remain to
be defined. In peritoneal mesothelial cells, corticosteroid
suppresses glucose-induced basic fibroblast growth factor
expression.6 To our knowledge, however, there has been no
investigation regarding the effect of glucocorticoids on MCP-
1 expression in peritoneal mesothelial cells.
The present study was designed to determine the
following: (1) the potential mechanisms responsible for the
initiation of peritoneal fibrosis, (2) the effects of glucose on
various intracellular signal pathways including MAPK, PKC,
and NF-kB in rat peritoneal mesothelial cells (RPMC), (3)
the pathway responsible for MCP-1 expression, and (4) the
molecular mechanism of prednisolone inhibition of glucose-
induced MCP-1 expression. The results indicate that glucose
induces MCP-1 expression through activation of PKC and its
downstream NF-kB and that prednisolone inhibits glucose-
induced MCP-1 expression through the inhibition of
GR-mediated activation of NF-kB by increasing I-kB-a
expression.
RESULTS
High glucose concentration-induced MCP-1 mRNA and
protein expression
First, we examined the time-dependent effects of high
glucose concentrations on the expression of MCP-1 mRNA.
RPMC were incubated for indicated times with 140 mM
(2.5%) glucose, which is the glucose concentration found
in commercial peritoneal dialysates. MCP-1 mRNA was
expressed at low levels in serum-starved RPMC in culture
medium containing normal glucose concentrations (5.6 mM).
However, MCP-1 mRNA expression increased rapidly in cell
culture media containing 140 mM glucose, from 1 h with a
peak noted at 3 h (484% of control, Po0.001) (Figure 1a).
The same concentrations of mannitol, a non-metabolizable
osmotic compound, also resulted in a similar and significant
increase in MCP-1 mRNA expression (445% of control,
Po0.001) (Figure 1a). We also examined the effect of
different concentrations of glucose and mannitol on MCP-1
mRNA expression. After a 3 h incubation of RPMC with the
indicated concentrations of glucose or mannitol, MCP-1
mRNA expression levels were similarly increased in both
groups in a concentration-dependent manner (Figure 1b).
In addition, we examined MCP-1 protein expression after
exposure of RPMC to 140 mM glucose or 140 mM mannitol
for the indicated times (Figure 2a). Although MCP-1 protein
levels in RPMC extracts did not change up to 24 h (data not
shown), those in culture media increased significantly at 6 h
after exposure, and remained increased up to 24 h (glucose,
356 pg/ml, Po0.0001; mannitol, 359 pg/ml, Po0.0001), after
MCP-1 mRNA expression reached a peak level at 3 h. We also
examined the effects of different concentrations of glucose
and mannitol on MCP-1 protein expression. After 24 h
incubation of RPMC with the indicated concentrations of
glucose or mannitol, MCP-1 protein expression levels were
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Figure 1 | Expression of MCP-1 mRNA by high glucose and
mannitol concentrations. Cultured RPMC were serum starved for
24 h and incubated with 140 mM glucose or 140 mM mannitol for the
(a) indicated times or with (b) indicated concentrations of glucose or
mannitol for 3 h. Extracted mRNAs were simultaneously assayed for
the expression of MCP-1 and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) by reverse transcription-polymerase chain reaction
(RT-PCR). The amount of PCR product was determined by scanning
densitometry and the relative ratio of MCP-1 to GAPDH band density
was calculated for each lane. Data are expressed as percentages of
the (a) amount of time 0 or (b) control (5.6 mM glucose or mannitol).
Values represent mean7s.d. (N¼ 4). *Po0.05; **Po0.001 versus
control. Open bars, glucose; solid bars, mannitol.
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increased in a concentration-dependent manner (Figure 2b).
Although the extent of the increase by mannitol was less than
that by glucose, there was no significant difference between
the effects of glucose and mannitol. We have previously
reported that 222 mM glucose exhibited significant cytotoxi-
city in RPMC; 222 mM glucose resulted in a decrease in G2/M
population, an increase in sub-G1 population, and an
increase in lactate dehydrogenase release,9 and for this reason
we selected glucose at 140 mM concentration in subsequent
experiments.
Role of PKC on high glucose concentration-induced MCP-1
expression
To explore the mechanism underlying the effects of high
glucose on MCP-1 expression, we examined the effects of
high glucose on activation of various intracellular signaling
molecules. The phosphorylation of MAPK kinase or extra-
cellular signal-regulated kinase kinase (MEK)1/2, p42/44
MAPK, p38 MAPK, c-Jun N-terminal kinase (JNK)1/2, and
PKC was examined by Western blot analysis using anti-
phospho antibodies (Figures 3a–e). High glucose rapidly
increased phosphorylation of each molecule in a time-
dependent manner, with a peak noted at 5 min for MEK1/2
(212% of time 0, Po0.05), 30 min for p42/44 MAPK (280%,
Po0.05), 5 min for p38 MAPK (163%, Po0.05), 30 min for
JNK1/2 (184%, Po0.05), and 15 min for PKC (160%,
Po0.05).
Next, we examined the role of each signaling molecule on
glucose-induced expression of MCP-1. RPMC were preincu-
bated with or without each inhibitor for MEK, PD98059;
JNK, SP600125; p38 MAPK, SB203580; or PKC, calphostin C,
for 30 min, and then stimulated with high-glucose-containing
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Figure 2 | Expression of MCP-1 protein by high glucose and
mannitol concentrations. RPMC were serum starved for 24 h and
incubated with 140 mM glucose or 140 mM mannitol for the
(a) indicated times or with (b) indicated concentrations of glucose
or mannitol for 24 h. Levels of MCP-1 protein in culture supernatants
were analyzed by enzyme-linked immunosorbent assay (ELISA).
Values represent mean7s.d. (N¼ 5). Open bars, glucose; solid bars,
mannitol. *Po0.001; **Po0.0001 versus time 0.
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Figure 3 | Effects of high glucose concentrations on the phosphorylation of intracellular signaling molecules. RPMC were serum starved
for 24 h and incubated with 140 mM glucose for the indicated times. Equal amounts of cell extracts (40 mg protein) were subjected to
electrophoresis and phosphorylation levels of (a) MEK1/2, (b) p42/44 MAPK, (c) p38 MAPK, (d) JNK1/2, and (e) PKC were assayed by Western
blotting using anti-phospho antibodies for each molecule. Relative phosphorylation levels were determined by densitometric analysis and are
presented as the relative ratio of phospho-MEK1/2, p42/44 MAPK, p38 MAPK, JNK1/2, and PKC to total MEK1/2, p42/44 MAPK, p38 MAPK, JNK1/
2, and PKC, respectively. The value at time 0 was set as 100% and the data are reported as percentages of the amount at time 0. Values
represent mean7s.d. (N¼ 5). *Po0.05 versus time 0.
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medium. Each inhibitor completely suppressed glucose-
induced activation of MEK1/2, p38 MAPK, JNK1/2, and
PKC (Figure 4a). We confirmed the specific inhibitory effect
of each inhibitor. PD98059, SP600125, SB203580, and
calphostin C specifically inhibited phosphorylation of MEK,
p38 MAPK, JNK, and PKC, respectively, without affecting
phosphorylation of other molecules (data not shown),
indicating that the concentrations used in the present study
produce specific inhibition of each of the respective signaling
molecules. Glucose-induced MCP-1 mRNA expression was
abolished only by calphostin C (increase by glucose was
inhibited by 84.9%, Po0.0001), but not by PD98059,
SP600125, and SB203580 (Figure 4b), suggesting that PKC
is responsible for mediating high-glucose-induced MCP-1
mRNA expression.
Role of NF-jB on high glucose concentration-induced MCP-1
expression
PKC has been reported to activate downstream transcrip-
tional factor, NF-kB, in many cell types. We therefore
examined the role of NF-kB on glucose-induced MCP-1
expression. Activation of NF-kB by high glucose was
confirmed by electrophoretic mobility shift assay (EMSA),
which revealed that incubation of RPMC with high-glucose-
containing medium increased DNA-binding activity of NF-
kB (155% of control, Po0.05; Figure 5, lane 3). The increase
in DNA-binding activity of NF-kB was completely sup-
pressed by PKC inhibitor, calphostin C, indicating that NF-
kB locates downstream of PKC in mediating glucose-induced
NF-kB activation (118% of control; Figure 5, lane 4). As a
specificity control, a 100-fold excess amount of unlabeled
cold probe was added as a competitor. The use of this control
resulted in complete competition for NF-kB DNA binding
(Figure 5, lane 6).
We then examined the effects of NF-kB inhibitors on
glucose-induced MCP-1 mRNA expression. To inhibit NF-kB
activity, RPMC were pretreated with either protease inhibitor
tosyl phenylalanyl chloromethylketone (TPCK), which has
been shown to inhibit interleukin (IL)-1-inducible NF-kB, or
antioxidant pyrrolidinedithiocarbamate (PDTC), which has
been shown to block phorbol ester-induced NF-kB activa-
tion.17 High-glucose-induced expression of MCP-1 mRNA
was partially suppressed by TPCK by 51% (Po0.05) and
PDTC by 68% (Po0.05), suggesting that NF-kB is involved
in mediating high-glucose-induced MCP-1 mRNA expres-
sion (Figure 6a). The suppression by PKC and NF-kB
inhibitors of glucose-induced MCP-1 mRNA expression
(Figures 4b and 6a) confirmed the effects of these inhibitors
on MCP-1 protein expression. Thus, MCP-1 protein expres-
sion was completely suppressed by the PKC inhibitor,
calphostin C, and partially by NF-kB inhibitors, PDTC or
TPCK, consistent with the results in MCP-1 mRNA (Figure
6b).
Effects of prednisolone on glucose-induced MCP-1 mRNA and
protein expression
We further investigated the effects of prednisolone on
glucose-induced MCP-1 expression.3 We initially confirmed
the expression of GR in cultured RPMC by RT-PCR, which
showed expression of GR mRNA in RPMC (Figure 7a). We
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MCP-1 mRNA expression. (a) RPMC were serum starved for 24 h and
pretreated with or without the indicated inhibitors (25 mM PD98059
for MEK, 30 mM SP600125 for JNK, 10 mM SB203580 for p38 MAPK,
0.33mM calphostin C for PKC) for 30 min before and during incubation
with 140 mM glucose. RPMC were incubated with glucose for 5 min
for MEK, 5 min for p38 MAPK, 30 min for JNK, or 15 min for PKC. Equal
amounts of cell extracts (40mg protein) were subjected to electro-
phoresis and phosphorylation levels of MEK1/2, p38MAPK, JNK1/2,
and PKC were assayed by Western blotting using anti-phospho
antibodies for each molecule. (b) RPMC were preincubated with or
without the indicated inhibitors for 30 min before incubating with
140 mM glucose for 3 h, and assayed for MCP-1 mRNA expression by
RT-PCR. Data represent mean7s.d. (N¼ 4). *Po0.0001.
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Figure 5 | EMSA of high-glucose-induced DNA-binding activity of
NF-jB. RPMC were serum starved for 24 h and nuclear extracts were
prepared from cells treated with or without 140 mM glucose for
90 min. Cells were preincubated with or without 0.33 mM calphostin or
1 mM prednisolone 30 min before adding glucose (lanes 4 and 5).
Equal amounts (5 mg of protein) of the nuclear extracts were assayed
for the ability to bind a biotin-labeled double-stranded NF-kB
oligonucleotide. As a specificity control, a 100-fold excess of
unlabeled probe was added (lane 6). The positions of NF-kB and free
probe are indicated. NS: nonspecific bands.
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also examined the effect of high glucose on the expression
level of GR to exclude the possibility that the effects of high
glucose might result from altered GR expression levels. High
glucose had no effects on GR mRNA and protein levels
throughout the experiment up to 24 h (Figures 7b and c).
The same concentration of mannitol (140 mM) had no effect
on GR protein expression levels (data not shown).
Next, we examined the effect of prednisolone on glucose-
induced MCP-1 mRNA expression. Prednisolone completely
inhibited high-glucose-induced MCP-1 mRNA expression in
a dose-dependent manner (Figure 8a). Suppression levels of
the increase were 85.4% in 0.1 mM prednisolone and 95.6% in
1 mM prednisolone. We subsequently examined whether this
prednisolone effect on MCP-1 mRNA expression was
mediated by prednisolone binding to GR. RPMC were
preincubated with the indicated concentrations of mifepris-
tone, a GR antagonist,23 followed by the addition of 140 mM
glucose and 1mM prednisolone. Mifepristone at 1 mM
significantly suppressed prednisolone inhibition of glucose-
induced MCP-1 mRNA expression, and more than 10 mM
concentrations of mifepristone completely attenuated the
effects of prednisolone (Figure 8b). In the absence of glucose,
mifepristone had no significant effects on MCP-1 mRNA
(data not shown) and protein expression (Figure 9).
Mifepristone also reduced the inhibitory effect of predniso-
lone on high-glucose-induced MCP-1 protein excretion
(Figure 9), indicating that the effects of prednisolone on
MCP-1 expression were mediated by prednisolone binding
to GR.
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Figure 6 | Effects of NF-jB inhibitors on high-glucose-induced
MCP-1 mRNA and protein expression. Serum-starved RPMC were
pretreated with or without calphostin C (0.33 mM), PDTC (50mM), or
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Mechanism of prednisolone inhibition of glucose-induced
MCP-1 expression
We further examined the molecular mechanism of the
inhibitory effects of prednisolone on glucose-induced
MCP-1 expression after binding of prednisolone to GR.
Prednisolone completely suppressed glucose-induced DNA-
binding activity of NF-kB as effectively as a PKC inhibitor,
calphostin C (Figure 5, lanes 4 and 5). However, prednisolone
had no effect on high-glucose-induced phosphorylation of
PKC (Figure 10a), suggesting that the effects of prednisolone
on glucose-induced MCP-1 expression were mediated by NF-
kB, downstream of PKC.
Glucocorticoids are known to inhibit NF-kB activation at
different levels. We therefore examined the mechanism of
prednisolone action on NF-kB. It has been postulated that
steroids inhibit NF-kB activation by increasing the transcrip-
tion of I-kB-a, an endogenous inhibitor of NF-kB.24,25
We initially examined the effect of prednisolone on the
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Figure 10 | The mechanism of prednisolone inhibition of glucose-induced MCP-1 expression. (a) Effect of prednisolone on high-glucose-
induced PKC phosphorylation. Serum-starved RPMC were preincubated with or without 1 mM prednisolone for 30 min and incubated with or
without 140 mM glucose for 15 min. Phosphorylation levels of PKC were assayed by Western blotting using a specific antibody against phospho-
PKC. Phosphorylation levels were expressed relative to the value at time 0. Values represent mean7s.d. (N¼ 5). *Po0.01. (b) Effects of
prednisolone on NF-kB and I-kB-a protein expressions. Serum-starved RPMC were incubated with 1 mM prednisolone for the indicated times.
Expression levels of NF-kB and I-kB-a were assayed by Western blotting. Expression levels are expressed relative to the value at time 0. Values
represent mean7s.d. (N¼ 4). *Po0.05; **Po0.01. (c) Dose response of prednisolone-induced I-kB-a protein expression and effects of glucose
and mannitol on prednisolone-induced I-kB-a protein expression. Serum-starved RPMC were preincubated with or without the indicated
concentrations of prednisolone for 30 min and incubated with glucose or mannitol for 6 h. Expression levels of NF-kB and I-kB-a were assayed
by Western blotting. Expression levels are expressed relative to the value without glucose, mannitol, or prednisolone. Values represent
mean7s.d. (N¼ 4). *Po0.05. (d) Effects of prednisolone on association of GR and NF-kB. Serum-starved RPMC were preincubated with or
without 1 mM prednisolone for 30 min and incubated with or without 140 mM glucose for 90 min. NF-kB was immunoprecipitated (IP) and
immunoblotted for NF-kB and GR (upper panel). Alternatively, GR was immunoprecipitated and immunoblotted for NF-kB and GR (lower
panel).
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expression of I-kB-a by Western blotting. The results showed
that prednisolone upregulated I-kB-a in a time-dependent
manner, but not the expression of NF-kB for up to 6 h
(Figure 10b). Prednisolone also increased I-kB protein
expression in a dose-dependent manner, without affecting
NF-kB expression (Figure 10c). Glucose and mannitol
slightly reduced, although not significantly, both I-kB and
NF-kB expression. Furthermore, prednisolone upregulated
I-kB even in the presence of high glucose and mannitol
concentrations. The activated GR is also reported to bind to
the p65 subunit of NF-kB, and thus interferes with the
binding of NF-kB to DNA and inhibits NF-kB-driven gene
expression.26 We therefore examined the binding of p65 NF-
kB to GR by co-immunoprecipitation. Our data showed a
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Figure 11 | Effects of hyperosmolarity on MCP-1 expression. (a) Effects of mannitol on PKC phosphorylation. RPMC were serum starved for
24 h and incubated with 140 mM mannitol for indicated times. Phosphorylation levels of PKC were assayed by Western blotting. Values
represent mean7s.d. (N¼ 5). *Po0.05 versus time 0. (b) EMSA of mannitol-induced DNA-binding activity of NF-kB. RPMC were serum starved
for 24 h and nuclear extracts were prepared from cells treated with or without 140 mM glucose for 90 min. Cells were preincubated with or
without 0.33 mM calphostin or 1 mM prednisolone 30 min before adding mannitol (lanes 3 and 4). Equal amounts (5 mg of protein) of nuclear
extracts were assayed for binding a biotin-labeled double-stranded NF-kB oligonucleotide. The positions of NF-kB and free probe are indicated.
NS: nonspecific bands. (c, d) Effects of PKC and NF-kB inhibitors on mannitol-induced MCP-1 mRNA and protein expression. Serum-starved
RPMC were pretreated with or without calphostin C (0.33mM), PDTC (50mM), or TPCK (5 mM) for 30 min, and incubated with 140 mM mannitol for
3 h (c) or 24 h (d). Expression levels of MCP-1 mRNA and protein were assayed by RT-PCR and ELISA, respectively. Values represent mean7s.d.
(N¼ 5). *Po0.05. (e, f) Effects of prednisolone on glucose- and mannitol-induced MCP-1 mRNA and protein. Serum-starved RPMC were
preincubated with or without 1 mM prednisolone for 30 min and incubated with or without 140 mM glucose or mannitol for (e) 3 h or (f) 24 h.
Expression levels of MCP-1 mRNA and protein were assayed by RT-PCR or ELISA, respectively. Values represent mean7s.d. (N¼ 4). *Po0.05.
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weak association of these molecules and no increase in the
binding by prednisolone treatment (Figure 10d), suggesting
that the effects of prednisolone were mediated by increasing
the transcription of I-kB-a, not by increasing the binding of
p65 NF-kB to GR in RPMC.
Effects of high osmolarity on MCP-1 expression levels
Finally, we examined the effects of high osmolarity on MCP-1
expression. Mannitol at concentration similar to that of
glucose produced glucose-equivalent increase in PKC phos-
phorylation levels, with a peak noted at 15 min (Figure 11a).
Mannitol also increased the DNA-binding activity of NF-kB
(Figure 11b). The latter effect was completely suppressed by
PKC inhibitor, calphostin C, and prednisolone. Mannitol also
increased MCP-1 mRNA and protein expression levels
(Figures 11c and d); the effects were completely abolished
by calphostin C and partially by PDTC or TPCK as seen in
glucose-induced MCP-1 mRNA and protein expression,
suggesting that PKC is essential and NF-kB is partially
involved in mediating mannitol-induced MCP-1 expression.
Likewise, prednisolone completely suppressed mannitol-
induced MCP-1 mRNA and protein expression (Figures 11e
and f), suggesting that high osmolarity contributes to the
regulation of MCP-1 expression, and that prednisolone has
similar inhibitory effects on glucose- and mannitol-induced
MCP-1 expression.
DISCUSSION
Glucocorticoid treatment prevents the progression of perito-
neal fibrosis and peritoneum adhesion;22 however, there have
been few investigations into the molecular mechanisms of
glucocorticoids in peritoneal fibrosis. It has been reported
that prednisolone suppresses glucose-induced basic fibroblast
growth factor and laminin expression in peritoneal meso-
thelial cells.6,27 To our knowledge, there has been no
investigation regarding the effects of glucocorticoids on
intracellular signal pathways and MCP-1 expression in
peritoneal mesothelial cells. Our study provides the first
evidence that prednisolone inhibits high-glucose-induced
MCP-1 expression by inhibiting the action of NF-kB in
peritoneal mesothelial cells. These results suggest that
prednisolone might be effective in preventing fibrosis in
patients receiving CAPD.
In the present study, we showed that glucose-induced
MCP-1 expression is mediated by PKC and NF-kB. Platelet-
derived growth factor induces MCP-1 expression via p42/44
MAPK, JNK, and p38 MAPK, suggesting that MAPK families
also play important roles in MCP-1 expression.13,28 However,
Ha et al.18 reported that glucose induces MCP-1 expression
via PKC and its downstream NF-kB pathway independent of
MAPK pathways, consistent with our results. Inhibition of
p42/44 MAPK, JNK, and p38 MAPK fails to suppress Toll-
like receptor-4-mediated MCP-1 expression.29 Furthermore,
IL-1b-induced MCP-1 expression via p38 MAPK is not
mediated by NF-kB,14 suggesting that p38 MAPK–CREB and
PKC–NF-kB independently regulate MCP-1 expression.
These reports indicate the involvement of several pathways,
in addition to MAPK, in the induction of MCP-1 expression.
NF-kB is a heterodimeric protein composed of different
combinations of members of the Rel family of transcription
factors.30 NF-kB dimers are sequestered in the cytosol of
unstimulated cells via non-covalent interactions with in-
hibitor proteins, called I-kBs. Degradation of I-kB proteins
allows NF-kB to move into the nucleus after phosphorylation
of I-kB. The mechanism of NF-kB suppression by gluco-
corticoids has been extensively reported. There are several
potential levels of interaction between steroids and NF-kB.
The activated GR binds to glucocorticoid-responsive ele-
ments in the promoter of the I-kB-a gene and induces the
expression of I-kB-a.24,25 This scenario is consistent with our
data showing that prednisolone enhanced the expression of
I-kB-a (Figure 10b). Thus, newly synthesized I-kB-a can
sequester NF-kB, thereby terminating NF-kB-dependent
transcriptional activation. Alternatively, activated GR directly
binds to NF-kB to prevent NF-kB binding to DNA.26
However, this hypothesis is unlikely to account for the results
observed in this study, because protein interaction between
GR and NF-kB was weak and was not increased by
prednisolone (Figure 10c). Transactivation by NF-kB de-
pends on the co-activators, cAMP-responsive element-
binding protein-binding protein and steroid receptor
co-activator-1, for maximal activity.31 GR-mediated repres-
sion of NF-kB-dependent gene expression results from
competition for a limited amount of these transcriptional
co-activators between NF-kB and GR. Glucocorticoids also
repress NF-kB-driven genes by disturbing the interaction of
NF-kB with the basal transcription machinery, irrespective of
co-activator levels.32 However, our data do not support these
potential mechanisms; these mechanisms interfere with the
transactivating potential of NF-kB without affecting DNA
binding, whereas prednisolone inhibited the DNA-binding
levels of NF-kB in the present study (Figure 5). Thus, our
results suggest that high-glucose-induced activation of NF-
kB is likely to be inhibited by prednisolone-induced
expression of the inhibitor, I-kB-a.
Expression of GR has been investigated in monocytes,33
mesangial cells,34 macrophages,35 and human umbilical vein
endothelial cells.36 In this study, we showed that RPMC
express GR as well as human peritoneal mesothelial cell,6 and
that the effect of prednisolone on MCP-1 expression was
reversed by a GR antagonist. These results suggest that the
effects of prednisolone are mediated by prednisolone binding
to GR. We also showed that glucose had no effect on GR
expression levels, suggesting that the inhibitory effects of
prednisolone on glucose-induced MCP-1 expression were not
due to altered expression levels of GR by high glucose levels.
NF-kB can be activated by exposure of cells to high
glucose levels, lipopolysaccharides, growth factors, inflam-
matory cytokines such as tumor necrosis factor or IL-1, viral
infection or expression of certain viral gene products, UV
irradiation, B- or T-cell activation, and by other physiological
and non-physiological stimuli.18,30 NF-kB regulates the
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expression of numerous proteins involved in inflammation
upon stimulation, which include cytokines (IL-6), chemo-
kines (IL-8, MCP-1, and regulated upon activation, normal T
cell expressed and secreted (RANTES)), and cell adhesion
molecules (intercellular adhesion molecule-1 and vascular
adhesion molecule-1).37 The signaling mechanisms mediat-
ing these effects include p42/44 MAPK, p38 MAPK, and
PKC.38,39 In the present study, glucose-induced expression of
MCP-1 was mediated by PKC and its downstream NF-kB.
Interestingly, glucose-induced MCP-1 expression was par-
tially suppressed by NF-kB inhibitors, TPCK by 51% and
PDTC by 68%, whereas a PKC inhibitor completely inhibited
MCP-1 expression, suggesting that there are other down-
stream pathways besides NF-kB such as AP-1. These results
are consistent with previous reports that high glucose induces
MCP-1 expression partly via the AP-1 pathway in human
mesothelial cells,20 and that cytokine induction of MCP-1
expression in human endothelial cells depends on the
cooperative action of NF-kB and AP-1.40 AP-1 is known to
be downregulated by glucocorticoid-activated GR;41 there-
fore, it might be an additional target of prednisolone
inhibition of glucose-induced MCP-1 expression.
MCP-1 is implicated in the progression of various human
and experimental glomerulonephritis42 and diabetic nephro-
pathy43 as well as peritoneal damage in patients on
CAPD10,12,44 by functioning as a major chemotactic factor
for monocytes/macrophages. Our results indicating that
prednisolone inhibits glucose-induced expression of MCP-1
suggest the potential efficacy of glucocorticoids in the
prevention of peritoneal fibrosis, because mesothelial cell-
derived chemokines such as MCP-1 might contribute to the
intraperitoneal recruitment of leukocytes in the initiation of
peritoneal inflammation that eventually leads to fibrosis.12
However, our data do not support a role for MCP-1 and
glucocorticoids in the later phase of fibrosis, because changes
in peritoneal morphology progressively develop during the
long-term course of CAPD therapy.1 In assessing the clinical
application of glucocorticoids, it would be important to
determine the role of MCP-1 in patients on long-term CAPD
use.
So far, the effects of mannitol on MCP-1 expression
remain controversial. Haslinger et al.19 reported that high
glucose induced MCP-1 expression whereas mannitol did not
influence MCP-1 expression levels in human mesothelial
cells. However, Wong et al.45 reported that glucose-mediated
induction of MCP-1 in human mesothelial cells is osmolarity
dependent. In the present study, mannitol had similar effects
on MCP-1 expression, suggesting that not only high glucose
concentration but also hyperosmolarity per se might play a
role in these effects. The use of the iso-osmolar glucose
polymer icodextrin, which is clinically used as an alternative
to glucose in peritoneal dialysis solutions, would be an
attractive way to avoid the effects of high osmolarity on
MCP-1 expression.
In conclusion, our results suggest that hyperosmolar
dialysates containing high glucose concentrations might be
involved in the initiation of peritoneal fibrosis, by inducing
MCP-1. As NF-kB activates many immunoregulatory genes
including MCP-1,38 specific inhibition of NF-kB activation
by glucocorticoids might be an attractive strategy for
therapeutic intervention of peritoneal fibrosis in patients
undergoing long-term CAPD therapy.
MATERIALS AND METHODS
Materials
Polyclonal antibodies for p42/44 MAPK, phospho- MEK1/2, MEK1/
2, and phospho-pan PKC and monoclonal antibody for phospho-
p42/44 MAPK were purchased from New England Biolabs (Beverly,
MA, USA). The monoclonal antibody for pan PKC was obtained
from Sigma (St Louis, MO, USA). Polyclonal antibodies for
phospho-p38 MAPK and phospho-c-Jun N-terminal kinase
(JNK)1/2 were purchased from BioSource International (Camarillo,
CA, USA). MEK inhibitor, PD98059, p38 MAPK inhibitor,
SB203580, JNK inhibitor, SP600125, and PKC inhibitor, calphostin
C, were purchased from Biomol Research Laboratories (Plymouth
Meeting, PA, USA). To inhibit NF-kB activation, antioxidant PDTC
(Sigma) or protease inhibitor TPCK (Sigma) was used. Prednisolone
and a GR antagonist, mifepristone, were obtained from Sigma. Anti-
p65 NF-kB, I-kB-a, and GR antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). D-Glucose and
D-mannitol were purchased from Nacalai (Tokyo, Japan) and used
for cell culture immediately after 0.2 mm filter sterilization to avoid
the effects of glucose degradation products.
Cell culture
RPMC were obtained and identified as described previously.9 RPMC
were maintained in Dulbecco’s modified Eagle’s medium containing
5.6 mM glucose, 10% fetal bovine serum, 100 U/ml penicillin, and
100 mg/ml streptomycin in 5% CO2 at 371C. To synchronize the cells
in quiescence, RPMC were maintained in Dulbecco’s modified
Eagle’s medium containing 0.5% fetal bovine serum for 24 h before
the experiments. RPMC were used between passages 3 and 6.
Western blotting, immunoprecipitation, and ELISA
Phosphorylation of MEK1/2, p42/44 MAPK, p38 MAPK, JNK1/2,
and PKC was analyzed by Western blotting using antibodies
recognizing phosphorylated forms of each signal molecule.46–48
The expression levels of I-kB-a and p65 NF-kB were analyzed by
Western blotting using anti-I-kB-a (1:1000) or p65 NF-kB (1:1000)
antibodies, respectively. Immunoprecipitation was performed using
anti-p65 NF-kB (5mg/ml) or GR (5mg/ml) antibodies using RIPA
buffer.46 Immunoprecipitates were analyzed by Western blotting
with anti-p65 NF-kB (1:1000) or GR (1:1000) antibodies. MCP-1
concentrations in the culture supernatants and cell extracts
of RPMC were measured by using an ELISA kit (BioSource
International).13
RT-PCR
RT-PCR was performed as described previously using the QuickPrep
mRNA purification kit (Amersham Pharmacia Biotech, Buckin-
ghamshire, UK) and a first-strand cDNA synthesis kit (Amersham
Pharmacia Biotech).13,49,50 Expression of MCP-1, GAPDH, and GR
mRNAs was determined by RT-PCR using specific primers as
described.6,13 PCRs for MCP-1 and GAPDH were simultaneously
performed for 24 cycles in the same microtubes under the following
conditions: 1 min at 951C, 45 s at 601C, and 45 s at 721C. PCR for
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GR was performed for 24 cycles: 1 min at 951C, 45 s at 601C, and 45 s
at 721C. Primer sets for MCP-1, GAPDH, and GR generated 595,
308, and 536 bp products, respectively.
Extraction of nuclear protein and EMSA
Nuclear extracts were prepared by using a nuclear extraction kit
(Sigma). EMSA was performed by using an EMSA Gel-Shift kit
(Panomics, Redwood City, CA, USA). Equal amounts (5mg each of
nuclear extract) were incubated with biotin-labeled double-stranded
NF-kB oligonucleotides (Panomics), and nucleoprotein–oligo-
nucleotide complexes were resolved by electrophoresis in 6% non-
denaturing polyacrylamide gels.
Statistical analysis
Data are expressed as mean7s.d. Differences between groups were
examined for statistical significance using one-way analysis of
variance or the Student’s t-test. A P-value less than 0.05 was
considered to represent a statistically significant difference.
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